JP2015526469A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526469A5
JP2015526469A5 JP2015528558A JP2015528558A JP2015526469A5 JP 2015526469 A5 JP2015526469 A5 JP 2015526469A5 JP 2015528558 A JP2015528558 A JP 2015528558A JP 2015528558 A JP2015528558 A JP 2015528558A JP 2015526469 A5 JP2015526469 A5 JP 2015526469A5
Authority
JP
Japan
Prior art keywords
composition
use according
placenta
heterologous
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015528558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/055632 external-priority patent/WO2014031553A1/en
Publication of JP2015526469A publication Critical patent/JP2015526469A/ja
Publication of JP2015526469A5 publication Critical patent/JP2015526469A5/ja
Pending legal-status Critical Current

Links

JP2015528558A 2012-08-20 2013-08-19 癌に対する胎盤ワクチン接種療法 Pending JP2015526469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691187P 2012-08-20 2012-08-20
US61/691,187 2012-08-20
PCT/US2013/055632 WO2014031553A1 (en) 2012-08-20 2013-08-19 Placental vaccination therapy for cancer

Publications (2)

Publication Number Publication Date
JP2015526469A JP2015526469A (ja) 2015-09-10
JP2015526469A5 true JP2015526469A5 (enExample) 2016-10-06

Family

ID=50150330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528558A Pending JP2015526469A (ja) 2012-08-20 2013-08-19 癌に対する胎盤ワクチン接種療法

Country Status (4)

Country Link
US (2) US20150216957A1 (enExample)
EP (1) EP2925332A4 (enExample)
JP (1) JP2015526469A (enExample)
WO (1) WO2014031553A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015142855A1 (en) * 2014-03-17 2015-09-24 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
WO2015168503A1 (en) * 2014-05-02 2015-11-05 Batu Biologics Compositions and means for induction of tumor immunity
US11298380B2 (en) * 2018-01-02 2022-04-12 Khloris Biosciences, Inc. IPSC-based vaccine as a prophylactic and therapeutic treatment for cancer
US11026980B1 (en) 2018-02-26 2021-06-08 Triad Life Sciences, Inc. Flowable birth tissue composition and related methods
CN114585373B (zh) 2019-05-06 2025-07-22 艾克塞利瑞提德生物技术公司 前体调节性细胞滋养层细胞及其用途
JP7787510B2 (ja) * 2021-03-12 2025-12-17 ドクタープロラボジャパン株式会社 プラセンタ抽出物の正常細胞増殖ヒト卵巣がん細胞増殖抑制用製剤の製造のための使用方法及び正常細胞増殖ヒト卵巣がん細胞増殖抑制用製剤の製造方法
CN115873790B (zh) * 2021-09-27 2026-01-02 金涌长生医学生物科技股份有限公司 一种蜕膜胎盘间充质干细胞及其在制备促进血管新生药物组合物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
IT1318405B1 (it) * 2000-03-17 2003-08-25 Piermario Biava Composizione antitumorale costituita da una frazione di utero gravidoo di placenta di mammiferi.
TWI310686B (enExample) * 2002-10-18 2009-06-11 You Ru Qian
WO2008002005A1 (en) * 2006-06-27 2008-01-03 Choongangbiotech Co., Ltd. A method for preparing pig placental extract to use as a feed additive and use thereof
JP2009035527A (ja) * 2007-08-01 2009-02-19 Snowden Co Ltd 動物胎盤抽出物よりなるアンドロゲン受容体結合阻害剤
WO2012018145A2 (ja) * 2010-08-05 2012-02-09 株式会社日本生物製剤 Qol改善剤

Similar Documents

Publication Publication Date Title
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
CO2018005258A2 (es) Vacuna del virus herpes simple
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
EP3792628A3 (en) Methods for predicting the usefulness of neoantigens for immunotherapy
GB2434367A (en) Improved vaccines
MY187462A (en) Modified virus-like particles of cmv
MX377144B (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
JP2012021028A5 (enExample)
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
Ren et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles)
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
HK1258860A1 (zh) 含有重组李斯特氏菌株的免疫治疗制剂的制作方法
Smith et al. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
WO2018065628A3 (en) Microbiota sequence variants of tumor-related antigenic epitopes
MX362820B (es) Antígenos recombinantes del circovirus porcino tipo 2 (pcv-2) para formulaciones de vacuna, kit de diagnóstico y uso.
EA201692375A1 (ru) Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов
Hu et al. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
JP2014516538A5 (enExample)
Yang et al. Display of streptococcus iniae α-enolase on the surface of virus-like particles (VLPs) of nervous necrosis virus (NNV) using SpyTag/SpyCatcher
CN106148258A (zh) mazG基因缺失的抗结核重组卡介苗
Kim et al. Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection